Appointment dossier — Uterine Carcinosarcoma
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Uterine Carcinosarcoma
- Carboplatin — Human evidence · 2 positive / 1 negative-mixed · PMID 38154864, 35007153, 33183764
- Paclitaxel — Human evidence · 2 positive · PMID 38154864, 35007153
- Trastuzumab Deruxtecan — Human evidence · 2 positive · PMID 39639215, 36977309
- Ifosfamide — Human evidence · 1 positive · PMID 35007153
- Trastuzumab-Deruxtecan (T-Dxd) — Human evidence · 1 positive · PMID 39639215
- Tamoxifen — Human evidence · 0 positive · PMID 11578496
- Pembrolizumab — Review evidence · 1 positive · PMID 32620662
- Sacituzumab Govitecan — Animal evidence · 1 positive · PMID 40344963
“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.
Open recruiting trials (18)
- NCT05902988 · Phase 1 / Phase 2 — A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer (United States)
- NCT03686124 · Phase 1 / Phase 2 — ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors (United States)
- NCT05269381 · Phase 1 / Phase 2 — Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (United States)
- NCT07262619 · Phase 1 / Phase 2 — EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors (United States)
- NCT07109726 · Phase 1 / Phase 2 — A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations (United States)
- NCT06840886 · Phase 1 — A Study of PHST001 in Advanced Solid Tumors (United States)
- NCT05518253 · Phase 1 — A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors (China)
- NCT06547840 · Phase 1 — A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha (United Kingdom)
- NCT07715747 · Phase 1 — A Study to Evaluate the Safety,Pharmacokinetics,Pharmacodynamics,and Efficacy of TJ037130 in Adult Participants With Advanced Solid Tumors (China)
- NCT07334119 · Phase 1 — Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors (Australia)
- NCT06349642 — Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform (United States)
- NCT05646316 · Phase 3 — Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer (United States)
- NCT03422198 · Phase 3 — Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer (United States)
- NCT07378098 · Phase 3 — to Evaluate the Efficacy and Safety of KLH-2109 in Patients With Uterine Fibroids and Menorrhagia (South Korea)
- NCT05559879 · Phase 1 / Phase 2 — Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma (United States)
- NCT03101995 · Phase 2 — Assessment of Gemcitabine as Chemoradiotherapy in Patients With Locally Advanced Carcinoma of Cervix and Renal Disease (Mexico)
- NCT06925724 · Phase 2 — A Study of Ivonescimab in People With Endometrial and Cervical Cancers (United States)
- NCT07594015 · Phase 2 — Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Progression on or Following First-Line Immunotherapy Maintenance (United States)
Most-relevant first: trials that name Uterine Carcinosarcoma, then broader trials you may still qualify for. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
For each medicine above, search manufacturer and nonprofit programs at medicineassistancetool.org.
Questions to ask your oncologist
- I've read that Carboplatin has been studied in people for Uterine Carcinosarcoma — what's the evidence, and is it an option or available in a trial for me?
- I've read that Paclitaxel has been studied in people for Uterine Carcinosarcoma — what's the evidence, and is it an option or available in a trial for me?
- I've read that Trastuzumab Deruxtecan has been studied in people for Uterine Carcinosarcoma — what's the evidence, and is it an option or available in a trial for me?
- Of the open trials I found (for example NCT05902988), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?